How does ImpriMed predict drug responses?

Our predictions are made by artificial intelligence (AI) models trained to predict clinical outcomes from patient data inputs.

Clinical outcomes collected from oncologists include reports of progressive disease, stable disease, partial response, and complete response.

Patient data used as inputs by the AI models include readings from our live-cell drug sensitivity assay, flow cytometry, PARR, and patient information.Models are re-trained periodically to incorporate new data and refine performance.

Other Questions

Back to Help Center

How does ImpriMed predict drug responses?

Our predictions are made by artificial intelligence (AI) models trained to predict clinical outcomes from patient data inputs. Clinical outcomes collected from oncologists include reports of progressive disease, stable disease, partial response, and complete response. Patient data used as inputs by the AI models include readings from our live-cell drug sensitivity assay, flow cytometry, PARR, and patient information.Models are re-trained periodically to incorporate new data and refine performance.

Why should I order ImpriMed services?

ImpriMed offers a unique precision oncology service that helps you to find the best anticancer drugs for your patients. ImpriMed directly tests a panel of commonly used anticancer drugs on your patients’ live cells in our A2LA accredited lab. In addition, we continually collect patient outcomes that are updated via regular follow-up with pet parents. As our database grows, so does the performance of our anticancer drug response predictions and your ability to develop a personalized treatment plan for each pet patient. So, when you order an ImpriMed service, you are actively contributing to our dataset and helping to improve cancer care for your patients and the ImpiMed user community.

Is there any reason to believe that submitting another sample to you would provide any additional information or possible changes in treatment protocols now that we are almost 4 months into the treatment plan?

We would suggest you submit another FNA and blood samples to us WHEN the patient's lymphoma relapses. Relapse of lymphoma means that the cancer develops a resistance to certain chemo drugs in use. When this happens, the relapsed cancer cells are usually different from the ones investigated in the naive status, which led to different drug response predictions to the tested drugs. Therefore, it would be better to get new tumor samples and find out what are the new preferred drugs and which of the used drugs still remain effective or became resistant for the relapsed lymphoma. However, the best scenario is to maintain clinical remission for as long a period of time so that you don’t have to order another service from us! If a second service is needed, we offer a 50% discount for returning patients.

I have a patient with likely lymphoma/leukemia. For a blood sample, can I just submit an EDTA blood tube or do I still use the ImpriMed tubes (and if so, how many tubes and is an additional EDTA blood tube still needed with that)?

If the patient is suspected of leukemia, blood collected in the EDTA tube should be fine. If it is lymphoma, we might need FNA from the affected organ/lymph node. We can suggest FNA in ImpriMed media tube (1) and 2ml of blood sample in an EDTA tube.

Can the test be used on cats and other animals?

At this time, we only offer commercial services to canine lymphoma patients. However, we are conducting research into feline lymphoma so if you would like to submit a sample please sign up here if you are interested in feline services.